[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638896":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":10,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1-Dexamethasone implant (DEX-I) Treatment",null,"Participants treated with dexamethasone implant (DEX-I).",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2 -aVEGF Treatment","Participants treated with anti-Vascular Endothelial Growth Factor (aVEGF).",{"label":16,"type":10,"description":17,"interventionNames":10},"Group 3 -aVEGF & DEX-I Treatment","Participants initially treated with aVEGF and then switched to DEX-I at 3-5 months.",[19],{"name":20,"affiliation":5,"role":21},"ABBVIE INC.","STUDY_DIRECTOR",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Andrew Shirlaw","CONTACT","844-663-3742","andrew.shirlaw@abbvie.com",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100638896",false,"NCT07604545","A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema","Predictive Value of OCT Inflammatory Biomarkers in DME Using AI Analysis","OPTIMAL-3","Inclusion Criteria:\n\n* Previously untreated Diabetic macular edema (DME) Participants.\n* Baseline macular edema ≥350 microns confirmed on Spectralis Standard deviation (SD)-Optical coherence tomography (OCT) or equivalent.\n* Baseline Best corrected visual acuity (BCVA) between 23 and 78 Early treatment diabetic retinopathy study (ETDRS) letters (between 20\u002F32 and 20\u002F230 Snellen).\n\nExclusion Criteria:\n\n* History of eyes with previous intravitreal or laser treatment for DME.\n* History of eyes with previous intraocular or periocular corticosteroid for DME.\n* History eyes with other macular disease, causing visual reduction or disturbance.","ALL","18 Years",{"count":40,"type":41},554,"ESTIMATED","OBSERVATIONAL","This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).",[45],"Diabetic Macular Edema",[45],"NOT_YET_RECRUITING","2026-05-18",{"date":50,"type":51},"2026-05-22","ACTUAL",{"date":53,"type":41},"2026-05-30",{"date":55,"type":41},"2027-03",{"name":5,"class":6}]